1. Engstrøm, M J, Ytterhus, B, Vatten, L J, Opdahl, S, Bofin, A M. 2014. TOP2A gene copy number change in breast cancer. In Journal of clinical pathology, 67, 420-5. doi:10.1136/jclinpath-2013-202052. https://pubmed.ncbi.nlm.nih.gov/24403186/
2. Cai, Hongyu, Zhu, Xinhua, Qian, Fei, Zhang, Yixin, Chen, Zhong. . High expression of TOP2A gene predicted poor prognosis of hepatocellular carcinoma after radical hepatectomy. In Translational cancer research, 9, 983-992. doi:10.21037/tcr.2019.12.46. https://pubmed.ncbi.nlm.nih.gov/35117443/
3. Bouchalova, Katerina, Cizkova, Magdalena, Cwiertka, Karel, Trojanec, Radek, Hajduch, Marian. . Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. In Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 153, 13-7. doi:. https://pubmed.ncbi.nlm.nih.gov/19365520/
4. Aumayr, Klaus, Klatte, Tobias, Neudert, Barbara, Susani, Martin, Haitel, Andrea. 2017. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas. In Pathology oncology research : POR, 24, 575-581. doi:10.1007/s12253-017-0260-0. https://pubmed.ncbi.nlm.nih.gov/28755093/
5. de Resende, Marina França, Vieira, Samantha, Chinen, Ludmilla Thomé Domingos, Brant, Xenia, Rocha, Rafael Malagoli. 2013. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. In Journal of translational medicine, 11, 36. doi:10.1186/1479-5876-11-36. https://pubmed.ncbi.nlm.nih.gov/23398928/
智鼠故事 
